ST诺泰被重罚 股民索赔持续推进

Core Viewpoint - Jiangsu Nuotai Aosaino Biopharmaceutical Co., Ltd. (ST Nuotai, stock code: 688076) has been penalized by the China Securities Regulatory Commission (CSRC) for significant violations, including false financial reporting and misleading public disclosures [1][5]. Group 1: Financial Misconduct - The 2021 annual report of Nuotai Biopharmaceutical contained false records, with a reported revenue of 30 million yuan from a technology transfer to Zhejiang Huabei Pharmaceutical, which lacked the financial capability to pay for the transaction [1][5]. - The technology transfer was deemed to lack commercial substance, leading to an inflated revenue of 30 million yuan and an inflated total profit of 25.9516 million yuan, representing 20.64% of the reported profit for that period [1][5][6]. Group 2: Regulatory Actions - The CSRC has ordered Nuotai Biopharmaceutical to rectify its practices, issued a warning, and imposed a fine of 47.4 million yuan. Additionally, six responsible individuals were fined a total of 28.8 million yuan [2][6]. Group 3: Investor Rights and Legal Recourse - Investors who suffered losses due to the company's false statements can file lawsuits for compensation, covering losses from price differences, commissions, and stamp duty [3][7]. - The eligibility for claims is set for investors who purchased Nuotai Biopharmaceutical shares between April 28, 2022, and October 23, 2024, and still held the shares by the latter date [3][7].